oxybutynin has been researched along with Scleroderma, Systemic in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pintea Bentea, G | 1 |
| Wauters, A | 1 |
| Wautrecht, JC | 1 |
| Cogan, E | 1 |
1 other study available for oxybutynin and Scleroderma, Systemic
| Article | Year |
|---|---|
Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients.
Topics: Administration, Cutaneous; Blood Flow Velocity; Case-Control Studies; Cold Temperature; Female; Hand | 2020 |